Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3. | J Clin Med | 2021 | 34442029 | PubTator, text mining | PubMed |
| Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. | Genes (Basel) | 2021 | 34440448 | PubTator, text mining | PubMed |
| CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2021 | 34439393 | PubTator, text mining | PubMed |
| Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. | Nat Cancer | 2021 | 34423310 | PubTator, text mining | PubMed |
| A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation. | Sci Immunol | 2021 | 34417258 | PubTator, text mining | PubMed |
| Determination of variable region sequences from hybridoma immunoglobulins that target Mycobacterium tuberculosis virulence factors. | PLoS One | 2021 | 34415957 | PubTator, text mining | PubMed |
| Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. | Front Oncol | 2021 | 34408978 | PubTator, text mining | PubMed |
| Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. | Cancer J | 2021 | 34398559 | PubTator, text mining | PubMed |
| The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications. | Cancer J | 2021 | 34398553 | PubTator, text mining | PubMed |
| Chronic lymphocytic leukaemia-what is new and notable in 2021, with a special focus on COVID-19. | Memo | 2021 | 34394761 | PubTator, text mining | PubMed |
| In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. | Front Oncol | 2021 | 34381700 | PubTator, text mining | PubMed |
| Immune2vec: Embedding B/T Cell Receptor Sequences in ℝ N Using Natural Language Processing. | Front Immunol | 2021 | 34367141 | PubTator, text mining | PubMed |
| The Biology of Classic Hairy Cell Leukemia. | Int J Mol Sci | 2021 | 34360545 | PubTator, text mining | PubMed |
| Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2021 | 34359757 | PubTator, text mining | PubMed |
| ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. | Cancers (Basel) | 2021 | 34359707 | PubTator, text mining | PubMed |
| Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. | Blood Cancer J | 2021 | 34354039 | PubTator, text mining | PubMed |
| Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. | Oncoimmunology | 2021 | 34350060 | PubTator, text mining | PubMed |
| Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. | Cell | 2021 | 34332650 | PubTator, text mining | PubMed |
| Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time-limited venetoclax/obinutuzumab treatment. | Clin Case Rep | 2021 | 34322260 | PubTator, text mining | PubMed |
| Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version). | Chin J Cancer Res | 2021 | 34321826 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=42